Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.

Abstract

Classic Parkinson's disease (PD) is characterized by fibrillar alpha-synuclein inclusions known as Lewy bodies in the substantia nigra, which are associated with nigrostriatal degeneration. However, alpha-synuclein pathologies accumulate throughout the CNS in areas that also undergo progressive neurodegeneration, leading to dementia and other behavioral impairments in addition to parkinsonism. Although mutations in the alpha-synuclein gene only cause Lewy body PD in rare families, and although there are multiple other, albeit rare, genetic causes of familial parkinsonism, sporadic Lewy body PD is the most common movement disorder, and insights into mechanisms underlying alpha-synuclein-mediated neurodegeneration provide novel targets for the discovery of disease-modifying therapies for PD and related neurodegenerative alpha-synucleinopathies.

• Authors: Virginia M-Y Lee, John Q Trojanowski
• Journal: Neuron (Neuron) Vol. 52 Issue 1 Pg. 33-8 (Oct 05 2006) ISSN: 0896-6273 [Print] United States
• PMID: 17015225 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• alpha-Synuclein

Topics

• Animals
• Drug Design
• Humans
• Lewy Bodies (genetics, metabolism, pathology)
• Models, Molecular
• Mutation (genetics)
• Parkinson Disease (metabolism, pathology)
• Plaque, Amyloid (pathology)
• alpha-Synuclein (genetics, metabolism)